Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial

CONCLUSIONS: IPE-PREVENTION CardioLink-14 provides the first translational evidence that IPE can modulate VR cell content and suggests a novel mechanism that may underlie the cardioprotective effects observed with IPE in REDUCE-IT.FUNDING: HLS Therapeutics provided the IPE in kind and had no role in the study design, conduct, analyses, or interpretation.PMID:38552629 | DOI:10.1016/j.medj.2024.03.009

Source: Pain Physician - March 29, 2024 Category: Anesthesiology Authors: Ehab Bakbak Aishwarya Krishnaraj Deepak L Bhatt Adrian Quan Brady Park Asaad I Bakbak Basel Bari Kristin A Terenzi Yi Pan Elizabeth J Fry Daniella C Terenzi Pankaj Puar Tayyab S Khan Ori D Rotstein C David Mazer Lawrence A Leiter Hwee Teoh David A Hess Su Source Type: research